Kidney Compass: Navigating Clinical Trials
Claim This Podcastby Kidney Compass: Navigating Clinical Trials
Podcast Authority
Beta
Podcast Overview
<div>Hosted by Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, Kidney Compass: Navigating Clinical Trials is a regular podcast exploring and breaking down the latest updates and nuances of clinical trials in nephrology. By listening to Kidney Compass, you'll get the guidance you need to navigate the changing landscape of clinical trials across the spectrum of kidney disease.</div>
Language
🇺🇲
Publishing Since
10/21/2024
Unlock The Full Podcast Authority Score Report
See how your podcast performs across key metrics
Podcast Authority
BetaRecommendations available
Unlock the full report to see detailed tips
Unlock comprehensive insights including:
- • YouTube presence analysis
- • Social media reach metrics
- • RSS compliance scoring
- • Podcast 2.0 features
- • Technical standards
Detailed Analytics
- Complete breakdown of all 19 authority metrics
- Personalized recommendations for each metric
- Industry benchmarks and comparisons
- Technical RSS feed analysis and compliance scoring
Growth Strategies
- Step-by-step action plans for improvement
- Quick wins to boost your score immediately
- Pro tips from successful podcasters
See how your show performs across every key metric
High authority scores make your podcast more attractive to industry leaders and influencers who want to appear on credible shows.
Sponsors look for podcasts with proven authority and engagement. Your score demonstrates your podcast's value to potential partners.
Understanding your strengths and weaknesses helps you make data-driven decisions to expand your listener base effectively.
1 verified contact email on file for Kidney Compass: Navigating Clinical Trials
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
Recent Episodes
April 14, 2026
REMODEL Trial Provides Mechanistic Rationale for Semaglutide in CKD
<div> <p>At the World Congress of Nephrology 2026 in Yokohama, Japan, growing attention is being paid not just to whether therapies improve outcomes in chronic kidney disease, but how they work at a mechanistic level. </p><p>In this episode of Kidney Compass, host Brendon Neuen, MBBS, PhD, spoke with David Cherney, MD, PhD, about the REMODEL trial, a mechanistic study designed to better understand the kidney-protective effects of semaglutide in patients with type 2 diabetes and chronic kidney disease.</p><p>0:00:00 – Episode intro & guest setup<br>0:00:54 – What is REMODEL & link to FLOW<br>0:01:21 – Design, outcomes & mechanistic readouts of REMODEL<br>0:04:30 – Additive effects with SGLT2 inhibitors<br>0:07:17 – Perirenal fat, venous pressure & “toxic adiposity”<br>0:10:28 – Relevance to non‑diabetic CKD & SMART trial link<br>0:13:20 – Clinical messaging & patient communication</p><p><a href="https://www.hcplive.com/view/kidney-compass-remodel-trial-provides-mechanistic-rationale-for-semaglutide-in-ckd">https://www.hcplive.com/view/kidney-compass-remodel-trial-provides-mechanistic-rationale-for-semaglutide-in-ckd</a></p></div>
April 14, 2026
IV Iron and Functional Outcomes in Kidney Transplant Recipients
<div> <p>Iron deficiency is increasingly recognized as a clinically meaningful yet underexplored contributor to morbidity in kidney disease, extending beyond its traditional association with anemia. In populations such as kidney transplant recipients, where graft function may be stable, many patients continue to experience impaired physical function, reduced quality of life, and lingering fatigue.</p><p>As evidence from other fields, particularly cardiology, has begun to demonstrate the benefits of intravenous iron on functional outcomes independent of hemoglobin, questions are emerging about whether similar strategies could improve how patients with kidney disease feel and function, not just how they measure on laboratory parameters.</p><p>In this episode of Kidney Compass recorded on-site at World Congress of Nephrology in Yokohama, Japan, hosts Shikha Wadhwani, MD, MS, and Brendon Neuen, MBBS, PhD, spoke with Martin de Borst, MD, PhD, about his investigator-initiated randomized trial of intravenous iron in kidney transplant recipients.</p><p>0:00:00 – Episode intro & topic framing<br>0:01:11 – Rationale & observational signals<br>0:03:03 – Choice of primary endpoint (6‑minute walk)<br>0:04:35 – Trial design & blinding details<br>0:05:11 – Inclusion criteria & population profile<br>0:07:48 – Dosing regimen & primary outcome result<br>0:09:03 – Secondary outcomes & “fixed labs, not patients”<br>0:12:32 – Lessons learned & future trial directions</p><p><a href="https://www.hcplive.com/view/kidney-compass-iv-iron-and-functional-outcomes-in-kidney-transplant-recipients">https://www.hcplive.com/view/kidney-compass-iv-iron-and-functional-outcomes-in-kidney-transplant-recipients</a></p></div>
April 14, 2026
New 2-Year APPLAUSE-IgAN Data for Iptacopan at WCN 2026
<div> <p>The treatment landscape for IgA nephropathy (IgAN) continues to evolve at a rapid pace, and new data presented at the World Congress of Nephrology (WCN) in Yokohama, Japan, suggest a potential shift in how clinicians approach disease modification in high-risk patients. </p><p>In this episode of Kidney Compass, hosts Shikha Wadhwani, MD, MS, and Brendon Neuen, MBBS, PhD, spoke with Vlado Perkovic, MBBS, PhD, about newly presented 2-year eGFR slope data from the phase 3 APPLAUSE-IgAN trial evaluating iptacopan.</p><p>0:00:00 – Episode intro & trial topic<br>0:00:52 – Overview of APPLAUSE trial & headline efficacy<br>0:02:40 – Hard outcome composite & safety profile<br>0:04:21 – Positioning iptacopan in guidelines & background therapy<br>0:05:10 – Consistency across subgroups & need for biomarkers<br>0:07:37 – Acute vs chronic eGFR slope with immunologic therapies<br>0:11:29 – Rationale for combination immunologic therapy<br>0:13:01 – Magnitude of effect, residual risk & early diagnosis</p><p><a href="https://www.hcplive.com/view/kidney-compass-new-2-year-applause-igan-data-for-iptacopan-at-wcn-2026">https://www.hcplive.com/view/kidney-compass-new-2-year-applause-igan-data-for-iptacopan-at-wcn-2026</a></p></div>
20 total episodes available
Similar Podcasts
Discover related shows you might enjoy
Deep-dive analytics for Kidney Compass: Navigating Clinical Trials
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is Kidney Compass: Navigating Clinical Trials?
<div>Hosted by Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, Kidney Compass: Navigating Clinical Trials is a regular podcast exploring and breaking down the latest updates and nuances of clinical trials in nephrology. By listening to Kidney Compass, you'll get the guidance you need to navigate the changing landscape of clinical trials across the spectrum of kidney disease.</div> - How often does this podcast release new episodes?
This podcast updates bi-weekly.
- Where can I listen to this podcast?
This podcast is available on 4 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
No, this podcast does not typically feature guests.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.